Stevens-Johnson Syndrome Associated With Long-Acting Sulfonamides

Oree M. Carroll, MD; Paul A. Bryan, MD; Robert J. Robinson, MD
JAMA. 1966;195(8):691-693. doi:10.1001/jama.1966.03100080131046.
Text Size: A A A
Published online

THE STEVENS-JOHNSON syndrome (erythema multiforme exudativum; Behçet syndrome)1 appears to be causally related to the use of the long-acting sulfonamides as well as other drugs and certain disease conditions.2,3 In an attempt to clarify this association and to delineate the scope of the problem, the Bureau of Medicine of the Food and Drug Administration has surveyed reports from the medical literature, reviewed adverse drug reaction data from other sources in the files of the FDA, and consulted various experts in the field. This communication is a summary of the data obtained and outlines FDA actions on the long-acting sulfonamides.

Background Considerations  The first long-acting sulfonamide was introduced to American medicine in 1957. At the present time, sulfamethoxypyridazine and sulfadimethoxine are in wide clinical use. These drugs require as little as one oral dose every 24 hours to maintain adequate therapeutic levels, thus differing markedly from the short-acting congeners.


Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
First page PDF preview




Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.